BioCentury
ARTICLE | Clinical News

GVAX: Phase II data

July 5, 2004 7:00 AM UTC

In a Phase II trial in 50 patients, those receiving GVAX plus cyclophosphamide trended toward an improvement in median time to progression and median survival. Eight of 20 patients receiving the combi...